Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Di Federico

Showing results (11-20 of 109) with videos related to

Pageof 11
Sort By:
Anti-Cancer Drugs|May 25, 2023
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinibAlessandro Di Federico, Andrea De Giglio, Francesca Sperandi, et al.
JTO Clinical and Research Reports|September 30, 2021
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-AnalysisAlessandro Di Federico, Andrea De Giglio, Claudia Parisi, et al.
Journal of the National Cancer Institute|November 2, 2022
Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysisAlessandro Di Federico, Andrea De Giglio, Francesco Gelsomino, et al.
Drugs in Context|August 1, 2022
Advanced non-small-cell lung cancer: how to manage non-oncogene diseaseAndrea De Giglio, Alessandro Di Federico, Chiara Deiana, et al.
Frontiers in Oncology|January 3, 2022
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, et al.
International Journal of Molecular Sciences|September 23, 2022
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)Andrea De Giglio, Marta Aprile, Alessandro Di Federico, et al.
Personalized Medicine|July 3, 2024
Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a <i>MET</i> exon 14 mutationNicole Conci, Virginia Marchiori, Alessandro Di Federico, et al.
Expert Opinion on Investigational Drugs|December 14, 2020
Nivolumab: an investigational agent for the treatment of biliary tract cancerAlessandro Di Federico, Alessandro Rizzo, Angela Dalia Ricci, et al.
Expert Opinion on Investigational Drugs|November 20, 2021
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trialsAlessandro Di Federico, Alessandro Rizzo, Riccardo Carloni, et al.
Future Oncology (London, England)|August 17, 2021
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysisAlessandro Di Federico, Andrea De Giglio, Giacomo Nuvola, et al.
Pageof 11

Showing results (11-20 of 109) with videos related to

Sort By:
Pageof 11
Anti-Cancer Drugs|May 25, 2023
Effective retreatment with osimertinib in CNS-relapsed epidermal growth factor receptor-mutant non-small cell lung cancer patient following resection and adjuvant osimertinibAlessandro Di Federico, Andrea De Giglio, Francesca Sperandi, et al.
JTO Clinical and Research Reports|September 30, 2021
Programmed Cell Death Protein-1 Inhibitors Versus Programmed Death-Ligand 1 Inhibitors in Addition to Chemotherapy for the First-Line Treatment of Advanced NSCLC: A Systematic Review and Meta-AnalysisAlessandro Di Federico, Andrea De Giglio, Claudia Parisi, et al.
Journal of the National Cancer Institute|November 2, 2022
Predictors of survival to immunotherapy and chemoimmunotherapy in non-small cell lung cancer: A meta-analysisAlessandro Di Federico, Andrea De Giglio, Francesco Gelsomino, et al.
Drugs in Context|August 1, 2022
Advanced non-small-cell lung cancer: how to manage non-oncogene diseaseAndrea De Giglio, Alessandro Di Federico, Chiara Deiana, et al.
Frontiers in Oncology|January 3, 2022
Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: Where Do We Stand?Alessandro Rizzo, Angela Dalia Ricci, Alessandro Di Federico, et al.
International Journal of Molecular Sciences|September 23, 2022
Impact of Baseline Versus Intercurrent Steroids Administration on Upfront Chemo-Immunotherapy for Advanced Non-Small Cell Lung Cancer (NSCLC)Andrea De Giglio, Marta Aprile, Alessandro Di Federico, et al.
Personalized Medicine|July 3, 2024
Efficacy and tolerability of capmatinib in a very elderly patient with metastatic NSCLC harboring a <i>MET</i> exon 14 mutationNicole Conci, Virginia Marchiori, Alessandro Di Federico, et al.
Expert Opinion on Investigational Drugs|December 14, 2020
Nivolumab: an investigational agent for the treatment of biliary tract cancerAlessandro Di Federico, Alessandro Rizzo, Angela Dalia Ricci, et al.
Expert Opinion on Investigational Drugs|November 20, 2021
Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trialsAlessandro Di Federico, Alessandro Rizzo, Riccardo Carloni, et al.
Future Oncology (London, England)|August 17, 2021
PD-(L)1 inhibitors as single-agent or in combination with chemotherapy for advanced, PD-L1-high non-small cell lung cancer: a meta-analysisAlessandro Di Federico, Andrea De Giglio, Giacomo Nuvola, et al.
Pageof 11